In the present study, taking advantage of the opportunity to study alive patients representing a well-defined and characterized model of oligometastatic disease, we have explored their immunologic characteristics, including HLA haplotypes, tumor immune microenvironment, and reactivity of peripheral lymphocytes against the differentially KRAS-mutated colon cancer cells. The gene discussed is KRAS; the disease is malignant colon neoplasm.